PharmX Technologies Limited (ASX: PHX) - Share Price
Current share price for PHX : $0.090 0.006 (6.25%)+
Pharmx Technologies Limited (PHX) is an ASX-listed company and is not held by any exchange traded funds (ETFs). It is a pharmacy ordering platform, providing essential infrastructure for seamless ordering and inventory management. By connecting the largest network of pharmacies, suppliers, and technology vendors, Pharmx facilitates $20bn in transactions annually through its robust, availability technology platform-driving efficient operations, seamless connectivity, and valuable insights across its ordering, eInvoicing, and analytics solutions.
PHX General Information +
| ASX Code | PHX |
| Website | http://www.pharmx.com.au |
| Industry/Sector | Application Software |
| Market Cap ($M) | 60 |
| PHX Share Price | $0.090 |
| Day High | $0.095 |
| Day Low | $0.088 |
| Last Close | $0.096 |
| PHX Share Price Movement | $0.01 ( 6.25% ) |
Prices as at 14:05, 6 Oct 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
PharmX Technologies Limited (PHX) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|---|---|---|---|---|---|---|
| Result | 0.5¢ | 30% | 11 Feb 2015 | 23 Feb 2015 | - | - | - |
| HFResult | 0.6¢ | 0% | 11 Aug 2014 | 25 Aug 2014 | - | - | - |
See all dividends from PharmX Technologies Limited (PHX) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
PharmX Technologies Limited (PHX) price-sensitive announcements
PHX - H1 FY26 Investor Presentation
PharmX Technologies Limited, trading as PHX, reported a 3% revenue growth for the half-yea
PharmX Technologies Limited (PHX)
25 Feb 2026 | 8:32 AM
25 Feb 2026 | 8:32 AM
PHX - H1 FY26 Results Announcement
PharmX Technologies Limited (ASX: PHX) reported its H1 FY26 results, highlighting a 3% rev
PharmX Technologies Limited (PHX)
25 Feb 2026 | 8:27 AM
25 Feb 2026 | 8:27 AM
PHX - Half Yearly Reports & Accounts
PharmX Technologies Limited reported its half-year results for the period ending 31 Decemb
PharmX Technologies Limited (PHX)
25 Feb 2026 | 8:26 AM
25 Feb 2026 | 8:26 AM
PHX - Pharmx and Sigma enter multi-year strategic alliance
PharmX Technologies Limited (ASX: PHX) has entered a multi-year strategic alliance with Si
PharmX Technologies Limited (PHX)
23 Feb 2026 | 8:27 AM
23 Feb 2026 | 8:27 AM
PharmX Technologies Limited (PHX) Recent ASX Announcements
PHX Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2026A | -$1.83 | -$0.30 | 625.00% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2025A | -$0.26 | N2 | -136.40% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | $0.65 | $0.10 | -466.70% | 34.30 | 0.00 | 0.00% | 0.0% |
PHX Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | ||
| Life360 Inc (360) | $3,556M | -32.1265 | -0.6998 | 0.9313 | 20.2281 | 67.3712 | 34.8837 | 0.00% | 0.00% | 0.00% |
| PharmX Technologies Limited (PHX) | $64M | 6.2500 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Technology One Limited (TNE) | $9,991M | 0.1582 | 0.1884 | 0.1742 | 73.1368 | 61.5447 | 52.4128 | 1.20% | 1.15% | 1.34% |
| Wisetech Global Limited (WTC) | $11,243M | 0.0801 | 0.2469 | 0.3254 | 29.1177 | 23.3515 | 17.6179 | 0.68% | 0.95% | 1.31% |
| Xero Limited (XRO) | $9,872M | 0.0000 | 0.0000 | 0.5457 | 0.0000 | 51.0006 | 32.9949 | 0.00% | 0.00% | 0.00% |
PHX Market Comparison
| Earnings | P/E Ratio | P/B Ratio | P/E Growth | |
|---|---|---|---|---|
| Company | 0.00 | 0.00 | 2.72 | 0.00 |
| Market | 0.37 | 13.80 | 1.07 | 0.71 |
| Sector | 1.53 | 21.00 | 2.26 | 0.73 |
PHX Directors
| Name | Position | Start Date |
|---|---|---|
| Mr Andrew Jonathan (Jon) George Newbery | Executive Director, Interim CFO | 25 Feb 2020 |
| Mr Nick England | Non-Executive Chairman, Non-Executive Director | 21 Nov 2019 |
| Ms Jayne Andrea Shaw | Non-Executive Director | 15 Oct 2020 |
| Mr Alexander (Sandy) Richmond Mellis | Non-Executive Director | 1 Sep 2025 |
| Mr Mark Conway | Non-Executive Director | 13 Mar 2026 |
PharmX Technologies Limited (PHX) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 12 Feb 2024 | ENGLAND, Nick | Buy | Indirect Shares | 127,500 | $0.015 | $1,912.500 |
| 11 Dec 2020 | NEWBERY, Jon | Buy | Direct Shares | 107,526 | $0.098 | $10,548.301 |
| 11 Dec 2020 | NEWBERY, Jon | Buy | Indirect Shares | 265,957 | $0.098 | $26,090.382 |
See all changes in directors' interest & trades for PharmX Technologies Limited (PHX) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
PHX Management
| Name | Position |
|---|---|
| Tom Culver | Chief Executive Officer |
| Zoe Hillier | Chief Financial Officer |
| Christopher Fernandes | Company Secretary |
PHX Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in -- (PHX). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 99,863,502 (16.69%) | Lujeta Pty Ltd |
| 65,810,168 (11%) | BNP Paribas Nominees Pty Ltd |
| 60,000,000 (10.02%) | Arrotex Investments Holding 1 |
PHX Calendar of Events
| Date | Event |
|---|---|
| 26 August 2027 | Report (Annual) |
| 26 August 2027 | Report (Prelim) |
| 24 February 2027 | Report (Interim) |
| 25 November 2026 | AGM |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
